Valerio Zenatti

Valerio Zenatti

Auto-generated profile, based on publicly available information

Valerio Zenatti

German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
LDLina Dinkel
Lina Dinkel
SHSelina Hummel
Selina Hummel
VZValerio Zenatti
Valerio Zenatti
MMMariagiovanna Malara
Mariagiovanna Malara
YTYannik Tillmann
Yannik Tillmann
STSabina Tahirovic
Sabina Tahirovic
Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder mainly driven by mutations in the NPC1 gene, causing lipid accumulation within late endosomes/lysosomes and resulting in progressive neurodegeneration. Although microglial activation precedes neuronal loss, it remains elusive whether loss of the membrane protein NPC1 in microglia actively contributes to NPC pathology. In a mouse model with depletion of NPC1 in myeloid cells, we report severe alterations in microglial lipidomic profiles, including the enrichment of bis(monoacylglycero)phosphate, increased cholesterol, and a decrease in cholesteryl esters. Lipid dyshomeostasis was associated with microglial hyperactivity, marked by an increase in translocator protein 18 kDa (TSPO). These hyperactive microglia initiated a pathological cascade resembling NPC-like phenotypes, including a shortened life span, motor impairments, astrogliosis, neuroaxonal pathology, and increased neurofilament light chain (NF-L), a neuronal injury biomarker. As observed in the mouse model, patients with NPC showed increased NF-L in the blood and microglial hyperactivity, as visualized by TSPO-PET imaging. Reduced TSPO expression in blood-derived macrophages of patients with NPC was measured after N -acetyl- l -leucine treatment, which has been recently shown to have beneficial effects in patients with NPC, suggesting that TSPO is a potential marker to monitor therapeutic interventions for NPC. Conclusively, these results demonstrate that myeloid dysfunction, driven by the loss of NPC1, contributes to NPC disease and should be further investigated for therapeutic targeting and disease monitoring.

16 August 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LBLaura M. Bartos
Laura M. Bartos
SQStefanie Quach
Stefanie Quach
VZValerio Zenatti
Valerio Zenatti
SKSabrina Viktoria Kirchleitner
Sabrina Viktoria Kirchleitner
JBJens Blobner
Jens Blobner
MBMatthias Brendel
Matthias Brendel
Purpose: Current therapy strategies still provide only limited success in the treatment of glioblastoma, the most frequent primary brain tumor in adults. In addition to the characterization of the tumor microenvironment, global changes in the brain of patients with glioblastoma have been described. However, the impact and molecular signature of neuroinflammation distant of the primary tumor site have not yet been thoroughly elucidated. Experimental Design: We performed translocator protein (TSPO)-PET in patients with newly diagnosed glioblastoma (n = 41), astrocytoma WHO grade 2 (n = 7), and healthy controls (n = 20) and compared TSPO-PET signals of the non-lesion (i.e., contralateral) hemisphere. Back-translation into syngeneic SB28 glioblastoma mice was used to characterize Pet alterations on a cellular level. Ultimately, multiplex gene expression analyses served to profile immune cells in remote brain. Results: Our study revealed elevated TSPO-PET signals in contralateral hemispheres of patients with newly diagnosed glioblastoma compared to healthy controls. Contralateral TSPO was associated with persisting epileptic seizures and shorter overall survival independent of the tumor phenotype. Back-translation into syngeneic glioblastoma mice pinpointed myeloid cells as the predominant source of contralateral TSPO-PET signal increases and identified a complex immune signature characterized by myeloid cell activation and immunosuppression in distant brain regions. Conclusions: Neuroinflammation within the contralateral hemisphere can be detected with TSPO-PET imaging and associates with poor outcome in patients with newly diagnosed glioblastoma. The molecular signature of remote neuroinflammation promotes the evaluation of immunomodulatory strategies in patients with detrimental whole brain inflammation as reflected by high TSPO expression.

15 October 2024
Verified
Other
Open access
LBLaura M. Bartos
Laura M. Bartos
SQStefanie Quach
Stefanie Quach
VZValerio Zenatti
Valerio Zenatti
SKSabrina Viktoria Kirchleitner
Sabrina Viktoria Kirchleitner
JBJens Blobner
Jens Blobner
MBMatthias Brendel
Matthias Brendel
Contralateral TSPO-PET signal elevation is associated with persisting epileptic seizures and worse overall survival. A, Contralateral TSPO-PET shows no quantitative difference between patients presenting with (n = 20) and without (n = 20) epileptic seizures at inital diagnosis (top). Significant increase of contralateral TSPO expression in patients experiencing persisting epileptic seizures after treatment of the primary tumor site (n = 8) compared to patients with discontinued seizures (n = 12; bottom). B, Heatmap of contralateral TSPO-PET signal in anatomically and functionally predefined brain regions (n = 15) of all patients experiencing epileptic seizures at initial diagnosis highlights two patients (age: in their 70s) with strongest contralateral TSPO expression. Coronal slices of TSPO-PET of these two patients are illustrated in comparison to group average images of patients with discontinued and persisting epileptic seizures after tumor therapy. White arrows point toward the tumor. C, Patients with persisting epileptic seizures indicate significant signal elevation in several contralateral brain regions with predominance in motor cortex, mesial temporal lobe, and occipital lobe compared to patients with discontinued epileptic seizures. *, P < 0.01. D, Matrix of regional TSPO-PET inter-correlation coefficients in comparison of patients with discontinued and persisting seizures as well as controls. Single boxes indicate interregional Pearson’s R. E, Significant increase of the contralateral TSPO-PET signal in patients with short overall survival (≤10.7 months; median split). F, High contralateral TSPO-PET signal (>0.88 SUVr; median split) at initial diagnosis is associated with worse overall survival in patients with glioblastoma. Multivariate Cox regression was adjusted for age, glucocorticoid medication, subsequent radiotherapy, and TSPO-PET signal of the tumor. **, P < 0.01. G and H, Distinct predictive value of contralateral TSPO-PET signal in different sub-regions on overall survival. *, P < 0.05.

15 October 2024
Verified
Other
Open access
LBLaura M. Bartos
Laura M. Bartos
SQStefanie Quach
Stefanie Quach
VZValerio Zenatti
Valerio Zenatti
SKSabrina Viktoria Kirchleitner
Sabrina Viktoria Kirchleitner
JBJens Blobner
Jens Blobner
MBMatthias Brendel
Matthias Brendel
Contralateral TSPO-PET signal elevation is associated with tumor phenotype and localization. A and B, Correlation of contralateral TSPO-PET signals in patients with glioblastoma (n = 38) with the TSPO-PET signal of the tumor (A) and the tumor volume in TSPO-PET, FET-PET (B, left), and MRI (B, right). C, Examples of TSPO-PET images derived from patients with distinct tumor extent and TSPO expression in PET indicate distinct contralateral PET signal elevation. D, Overall correlation between corresponding areas of the tumor and the contralateral hemispheres including all 123 brain sub-regions of each individual patient. E, Correlation of regionally defined tumor seed regions with TSPO-PET signals of the 123 sub-regions in the contralateral hemisphere. Surface projection of tumor seed localization (top rows: seed region, colored in black) and corresponding contralateral coefficients of correlation (bottom rows). IFG, inferior-frontal gyrus; ITG, inferior-temporal gyrus; MesTemp, mesio-temporal; MFG, mid-frontal gyrus; Motor, motor area; MTG, mid-temporal gyrus; OFG, orbitofrontal gyrus; SFG, superior-frontal gyrus; STG, superior-temporal gyrus. F, Correlation of both hemispheres within 15 previously defined anatomically and functionally connected brain regions. Highest coefficients of correlation are colored in red, significant correlations are highlighted by thick boundaries.

15 October 2024
Verified
Other
Open access
LBLaura M. Bartos
Laura M. Bartos
SQStefanie Quach
Stefanie Quach
VZValerio Zenatti
Valerio Zenatti
SKSabrina Viktoria Kirchleitner
Sabrina Viktoria Kirchleitner
JBJens Blobner
Jens Blobner
MBMatthias Brendel
Matthias Brendel
Back-translation into a glioblastoma mouse model pinpoints myeloid cells as the cellular source of contralateral TSPO-PET signal elevations. A, Glioblastoma mice (n = 15) show higher TSPO-PET signal in the contralateral hemisphere compared to sham injected animals (n = 14). B, Coronal slices of group average TSPO-PET images of SB28 glioblastoma mice (top row; n = 15) and sham injected mice (bottom row; n = 14). Analyzed planes are indicated upon a CT template. Arrows point to the PET signal elevation in the contralateral hemisphere of SB28 mice. Tumor hemisphere is blurred. C, Whole brain tumor seed correlation analysis shows dependency of contralateral TSPO-PET signals (white arrows) from tumor TSPO-PET signals in SB28 mice (n = 15). Tumor TSPO-PET signals were extracted using a spherical volume of interest with 1.5 mm diameter and included as a seed in a voxel-wise statistical parametric mapping regression model. D, CD11b positive myeloid cells of the contralateral hemisphere of glioblastoma mice (n = 13) show higher single-cell TSPO tracer uptake than myeloid cells of sham injected (n = 14) or healthy control mice (n = 8; left). Non-myeloid cells show no difference in TSPO tracer uptake between the three conditions (right). E and F, Immunohistochemistry shows higher myeloid cell abundance and increased TSPO in IBA1 positive myeloid cells in contralateral hemispheres of SB28 glioblastoma mice (n = 3) compared to sham (n = 4). G, qPCR was used to exclude infiltration of SB28 glioblastoma cells into the contralateral hemispheres in SB28 glioblastoma mice (n = 8; left). Tumor tissue was used as a positive control. While tumor cells could only be detected in the tumor tissue, TSPO expression was observed in contralateral hemispheres of SB28 glioblastoma mice and exceeded TSPO expression in sham injected (n = 4) and healthy control mice (n = 4, right). (Adapted from an image created with BioRender.com.)

15 October 2024
Verified
Other
Open access
LBLaura M. Bartos
Laura M. Bartos
SQStefanie Quach
Stefanie Quach
VZValerio Zenatti
Valerio Zenatti
SKSabrina Viktoria Kirchleitner
Sabrina Viktoria Kirchleitner
JBJens Blobner
Jens Blobner
MBMatthias Brendel
Matthias Brendel
Contralateral hemispheres of SB28 glioblastoma mice indicate signatures of disease-associated myeloid cells and immunosuppression. A, Volcano plot highlights genes with significant upregulation and downregulation in the contralateral hemisphere of SB28 glioblastoma mice (red and blue, respectively) compared to sham. B, qPCR reveals higher expression of genes related to an inflammatory myeloid cell state in contralateral hemispheres of SB28 glioblastoma mice in contrast to sham. C, Illustration of the 50 pathways with highest elevation in immune cells of the contralateral hemisphere of SB28 glioblastoma mice (informed by IPA). Note that 40 out of the 50 pathways with highest activation were related to cell migration (phagocytes, leukocytes), phagocytosis, and immune cell activation (indicated in blue). D, IPA network analysis based on altered gene expression signatures in contralateral hemispheres of SB28 glioblastoma mice in contrast to sham. Depicted is a network plot showing TSPO-mediated associations with poor prognosis (e.g., CCL2) and immunosuppression (e.g., CHI3L1).